Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

This study has been completed.
Information provided by (Responsible Party):
Savient Pharmaceuticals Identifier:
First received: October 27, 2008
Last updated: October 28, 2011
Last verified: October 2011
This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.

Condition Intervention Phase
Biological: pegloticase
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout

Resource links provided by NLM:

Further study details as provided by Savient Pharmaceuticals:

Primary Outcome Measures:
  • Uric Acid (mg/dL) [ Time Frame: Week 13, Week 25, Week 53, Week 101 ]
    Uric acid measured at 3 month-intervals

Secondary Outcome Measures:
  • Tophus Response [ Time Frame: Up to 2 years ]
    Target tophi evaluated during the randomized, controlled study were followed for response at 3, 6, 12, 18 and 24 months in this open-label extention study. Results from each participant's final assessment on drug are reported (as last observation carried forward). Complete response=complete disappearance of at least one tophus with no new or worsening tophus. Partial Response=a 50% or more decrease in at least one tophus with no new or worsening tophus.

  • Patient Reported Outcome: SF-36 Physical Component Summary Score [ Time Frame: RCT Week 25; OLE Week 25; OLE Week 53, OLE Week 77, OLE Week 101 ]

    SF-36 is the Medical Outcomes Survey Short Form-36, a 36-item self-reported questionnaire which assesses health-related limitations in 8 dimensions. The Physical Component Summary Score (PCS) is a composite summary score derived from the dimensions related to physical functioning outcomes: Physical Function, Role Physical, General Health and Bodily Pain (each with a 0 to 100 scale where 0=worst, 100=best).

    The Summary Score is constructed as a T-score with a mean of 50 and standard deviation of 10, where higher scores indicate a better health status.

  • Gout Flare Frequency [ Time Frame: Up to 2 years ]
    The the mean number of flares per subject (flare frequency)was assessed over 3-month periods for up to 2 years of treatment

  • Gout Flare Incidence [ Time Frame: Assessed in 3-month intervals up to 2 years ]
    Percentage of participants remaining in the study during the specified interval who experienced a gout flare during this interval.

Enrollment: 151
Study Start Date: December 2006
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: q2 RCT
Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
Biological: pegloticase
8 mg intravenous infusion
Experimental: q4 RCT
Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
Biological: pegloticase
8 mg intravenous infusion
Experimental: Placebo in RCT
Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
Biological: pegloticase
8 mg intravenous infusion


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed treatment in one of two double-blind, placebo controlled studies of PEG-uricase in subjects with hyperuricemia and symptomatic gout

Exclusion Criteria:

  • unstable angina
  • uncontrolled arrhythmia
  • uncontrolled hypertension
  • end stage renal disease requiring dialysis
  • anemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01356498

United States, California
Kaiser Permanente Medical Center, Clinical Trials Unit
San Francisco, California, United States, 94118
Pacific Arthritis Center Medical Group
Santa Maria, California, United States, 93454
Agilence Arthritis & Osteoporosis Medical Center
Whittier, California, United States, 90606
United States, District of Columbia
Veterans Affairs Medical Center
Washington, District of Columbia, United States, 20422
United States, Florida
Arthritis & Rheumatic Disease Specialties
Aventura, Florida, United States, 33180
Ocala Rheumatology Research Center
Ocala, Florida, United States, 34474
St. Petersburg Arthritis Center
St. Petersburg, Florida, United States, 33703
United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
United States, Kentucky
Graves Gilbert Clinic
Bowling Green, Kentucky, United States, 42101
United States, Maryland
Peter A. Holt, M.D.
Baltimore, Maryland, United States, 21239
Center for Rheumatology and Bone Research
Wheaton, Maryland, United States, 20902
United States, Michigan
Justus J. Fiechtner, MD, PC
Lansing, Michigan, United States, 48910
United States, Minnesota
CentraCare Clinic
St. Cloud, Minnesota, United States, 56377
United States, New Jersey
Rheumatology Associates of North Jersey
Teaneck, New Jersey, United States, 07666
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27302
United States, Ohio
New Horizons Clinical Research
Cincinnati, Ohio, United States, 45242
The Ohio State University
Columbus, Ohio, United States, 43210
STAT Research, Inc.
Dayton, Ohio, United States, 45402
David R. Mandel, MD, Inc.
Mayfield Village, Ohio, United States, 44143
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Mid Atlantic Research Assoc.
Philadelphia, Pennsylvania, United States, 19154
United States, Washington
Arthritis Northwest, PLLC
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Savient Pharmaceuticals
Study Director: Medical Director, M.D. Savient Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Savient Pharmaceuticals Identifier: NCT01356498     History of Changes
Other Study ID Numbers: C0407
Study First Received: October 27, 2008
Results First Received: August 5, 2011
Last Updated: October 28, 2011

Keywords provided by Savient Pharmaceuticals:
chronic gout

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases processed this record on April 25, 2017